CTSOCTSOHealthcare · Medical Devices

CTSO Stock Forecast: CytoSorbents Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$4.16

The median 12-month analyst price target for CytoSorbents Corp. is $33. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 70 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$16.2M
Ticker Nerd rank
70/ 100
Median analyst target
$33
Analysts covering
1
Revenue$9.6M+0.2% y/y
Operating income−$2.4M
Net income−$4.4M
Free cash flow−$635K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores CytoSorbents Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
70/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
93
Revisions
68
Growth
66
Quality
56
Value
53
Volatility
36
Momentum
35
Issuance
21

Accruals (93): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (21): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CTSO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTSO, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
0
Buy
1
Hold
0
Sell
$15
Low
$33
Median
$50
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Oct 2026WBB SecuritiesInitiatesSpeculative Buy$9.50
26 Mar 2026D. Boral CapitalMaintainsBuy$10
12 Jan 2026D. Boral CapitalMaintainsBuy—
16 Dec 2025D. Boral CapitalMaintainsBuy—
14 Nov 2025D. Boral CapitalMaintainsBuy—
14 Nov 2025HC Wainwright & Co.MaintainsNeutral—
16 Sept 2025D. Boral CapitalMaintainsBuy—
20 Aug 2025D. Boral CapitalMaintainsBuy—
8 Aug 2025D. Boral CapitalMaintainsBuy—
21 July 2025D. Boral CapitalMaintainsBuy—
25 June 2025D. Boral CapitalMaintainsBuy—
15 May 2025D. Boral CapitalMaintainsBuy—
15 May 2025HC Wainwright & Co.ReiteratesNeutral—
2 May 2025D. Boral CapitalMaintainsBuy—
3 Apr 2025HC Wainwright & Co.ReiteratesNeutral—
1 Apr 2025D. Boral CapitalMaintainsBuy—
25 Feb 2025D. Boral CapitalMaintainsBuy—
13 Jan 2025D. Boral CapitalMaintainsBuy—
3 Jan 2025D. Boral CapitalMaintainsBuy—
12 Nov 2024D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CTSO.

Market Radar

This page is one stock. Monday covers all of them.

CTSO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

CTSO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.4×

Cheaper than 82% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
2.6%

Higher than 34% of US stocks

Earnings growth (YoY)
—
Gross margin
73.2%

Higher than 85% of US stocks

Operating margin
−27.7%

Higher than 21% of US stocks

Net margin
−45.1%

Higher than 11% of US stocks

Returns & dividend
Return on equity
—
Return on assets
−15.6%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CytoSorbents Corp. has a market value of $16.2M and an enterprise value of $41.5M.

  • Revenue in the twelve months to 30 June 2026: $37.2M. The latest quarter grew 0.2% year on year.

  • Net income over the same four quarters: −$18.2M, a −48.9% net margin.

  • Diluted earnings per share, trailing twelve months: −$5.80.

  • Free cash flow in the twelve months to 30 June 2026: −$9.6M.

  • Shares outstanding: 3.1M.

  • CytoSorbents Corp. employs 129 people — $288K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CTSO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CTSOCytoSorbents Corp.$16.2M70
SNWVSANUWAVE Health, Inc.$12.9M53
CVRXCVRx, Inc.$14.3M20
ITOCiTonic Holdings Ltd.$11.6M15
MODDModular Medical, Inc.$16.0M12
HSCSHeartSciences, Inc.$10.3M43
NNOXNano-X Imaging Ltd.$17.7M17

Take a look at CTSO’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own CytoSorbents Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CTSO

What is the CTSO stock price forecast for 2026-2027?

The median 12-month analyst price target for CytoSorbents Corp. is $33, with estimates ranging from $15 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTSO stock a buy right now?

Of the 1 analyst covering CytoSorbents Corp., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CytoSorbents Corp. 70 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTSO?

As at 21 Nov 2026, CytoSorbents Corp. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (93 of 100).

Will CTSO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $33, and Ticker Nerd's factor model ranks CytoSorbents Corp. 70 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTSO stock forecast for 2030?

No analyst covering CytoSorbents Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTSO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $50 over the next 12 months.

What does CytoSorbents Corp. do?

CytoSorbents Corporation is a medical device company focused on blood purification technologies for critical care and cardiac surgery. CytoSorbents Corporation develops and commercializes products that use hemoadsorption to remove harmful substances from blood, including inflammatory mediators, bilirubin, myoglobin, and certain antithrombotic drugs.

Company

About CytoSorbents Corp.

CytoSorbents Corporation is a medical device company focused on blood purification technologies for critical care and cardiac surgery. CytoSorbents Corporation develops and commercializes products that use hemoadsorption to remove harmful substances from blood, including inflammatory mediators, bilirubin, myoglobin, and certain antithrombotic drugs. Its portfolio includes CytoSorb for intensive care and surgical applications, DrugSorb-ATR for removing blood thinners, and additional blood purification and filtration technologies for specialized clinical and veterinary uses. The company serves hospitals and clinicians in the United States, Europe, and other international markets, with an emphasis on treating life-threatening conditions such as sepsis, severe inflammation, and complications associated with surgery and organ failure. Headquartered in Princeton, New Jersey, CytoSorbents Corporation plays a niche role in the medical technology market through its proprietary polymer-based adsorption platform.

CEO Dr. Phillip P. Chan M.D., Ph.D. · 129 employees · United States · https://www.cytosorbents.com